Tirzepatide vs CagriSema: peptide comparison

Data-derived verdict

Tirzepatide has stronger documented evidence (FDA-Approved) than CagriSema (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Tirzepatide is the safer pick. CagriSema may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Tirzepatide

FDA-Approved

CagriSema

Phase 3

FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged

Side-by-side

	Tirzepatide	CagriSema
Class	GIP/GLP-1 dual incretin agonist	Amylin + GLP-1 combination
Drug class	Metabolic & Weight	Metabolic & Weight
Mechanism	Dual agonism at GIP and GLP-1 receptors; delays gastric emptying; enhances satiety; improves insulin sensitivity [1][2]	Dual amylin + GLP-1 receptor agonism
Route	SC injection	SC injection
Half-life	~5 days	~7 days
Dosage (research)	2.5 mg SC weekly (Mounjaro/Zepbound label starting dose, escalate by 2.5 mg monthly to label max 15 mg weekly per SURMOUNT escalation schedule) [1][2][3]	2.4 mg / 2.4 mg SC weekly
Evidence tier	FDA-Approved	Phase 3
Research depth	262 indexed (PubMed 147 · CT 50 · EPMC 65)	108 indexed (PubMed 35 · CT 30 · EPMC 43)
Availability	Prescription	Investigational
Reported risks	Nausea; vomiting; diarrhea; pancreatitis risk; gallbladder disease; thyroid C-cell tumor black-box warning [1][2]	GI effects; Phase 3 REDEFINE mixed results

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Tirzepatide or CagriSema?

Tirzepatide has stronger documented evidence (FDA-Approved) than CagriSema (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Tirzepatide is the safer pick. CagriSema may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Tirzepatide and CagriSema?

Tirzepatide is classed as GIP/GLP-1 dual incretin agonist; CagriSema is classed as Amylin + GLP-1 combination. Reported mechanism: Tirzepatide, Dual agonism at GIP and GLP-1 receptors; delays gastric emptying; enhances satiety; improves insulin sensitivity; CagriSema, Dual amylin + GLP-1 receptor agonism. Reported half-life: Tirzepatide, ~5 days; CagriSema, ~7 days. Routes in published studies: Tirzepatide, SC injection; CagriSema, SC injection.

Which has stronger evidence, Tirzepatide or CagriSema?

Tirzepatide has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Tirzepatide is graded FDA-Approved, with 66 cited sources on its reference page and 262 indexed studies. CagriSema is graded Phase 3, with 22 cited sources on its reference page and 108 indexed studies.

Which is more accessible, Tirzepatide or CagriSema?

Tirzepatide is FDA-approved and CagriSema is not. Catalog status: Tirzepatide, Prescription; CagriSema, Investigational.

Are Tirzepatide and CagriSema ever combined?

Tirzepatide and CagriSema appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.